Introduction
Retinitis pigmentosa (RP, OMIM 268000) is a group of hereditary retinal diseases characterized by progressive loss of rod and cone photoreceptor cells. It is relatively common, and the worldwide incidence is 1 in 4,000 people worldwide. Patients usually present with night blindness and complain about progressive constriction of their visual field. Central vision is eventually affected and then declines. Clinical features vary dramatically among individuals.
Although RP usually affects the eye alone (nonsyndromic), approximately 20-30% of RP cases is also related with other diseases not involving the eye (syndromic). Inheritance patterns include autosomal recessive (20%), autosomal dominant (10-20%), or an X-linked recessive pattern (10%). Up to 40% of cases are defined as simplex RP, which has no family history. Most cases of simplex RP may be caused by autosomal recessive inheritance. If sporadic RP is considered autosomal recessive, the approximate proportions change as follows: 30-40% autosomal dominant, 50-60% auto-and mutations identified as well as non-Mendelian inheritance patterns such as digenic inheritance or incomplete penetrance. For example, different mutations in the same gene can generate different phenotypes, and the same mutation in different individuals may cause distinctly different symptoms. Moreover, genetic diversity among populations differing in ethnicity and geographical location is also problematic. 3, 4) Therefore, to identify the mutations that cause RP, comprehensive approaches and meticulous validation are required.
In the present review, we attempt to describe the major methodologies available for discovering genetic abnormalities in retinitis pigmentosa with particular emphasis on next-generation sequencing -based exome sequencing.
Positional Cloning
A disease gene that is inherited in Mendelian fashion can be identified knowing nothing but its approximate chromosomal location. The first step of positional cloning is defining the candidate region and identifying all the genes that reside within. The success of positional cloning depends upon whether the disease is closely related to known genetic markers, which is difficult to predict. Targeted genes are prioritized for screening for mutations and then verifying their presence in the affected patient.
Genetic mapping by linkage analysis
Linkage analysis was first applied in 1985 for identifying the gene responsible for X-linked chronic granulomatous disease. 5) The first discovery of the mutation that causes autosomal dominant RP (RhoPro23His in RHO) was reported by Dryja et al. 6) and was based on the finding that a large pedigree of autosomal dominant RP is linked to an anonymous polymorphic sequence from the long arm of chromosome 3. Moreover, the gene encoding rhodopsin is also assigned to that region. Peripherin/RDS, RP1, and PRPF3 mutations were also identified as causative for dominant RP using linkage mapping. [6] [7] [8] Linkage analysis is a powerful tool for identifying Mendelian mutations, because it is relatively easy to perform. However, its application is limited to affected large families.
Genetic positioning by homozygosity mapping
Homozygosity mapping is an efficient strategy to identify mutations associated with autosomal recessive traits in consanguineous families. This has enabled mapping of many recessive diseases, which would have been otherwise difficult in the absence of adequate numbers of affected families with multiple affected members. 9) Several rare causal genes like C2orf71, C9ORF37, FAMA161A, IMPG2, and RBP3 are identified using homozygosity mapping. [10] [11] [12] [13] [14] [15] 
Candidate gene approach
The candidate gene approach involves targeting a gene based on biochemical knowledge, such as the function of or tissue-specific expression of its encoded protein. The most promising genes are prioritized and analyzed to find genetic variants. Computer analysis has been employed to search for and classify candidate genes using public domain databases. 16) The direct confirmation of genetic alteration in candidate gene may be a sequencing. We will discuss the sequencing in detail at latter part of this text. Before that, several representative screening tools used to detect mutations in candidate regions are explained here.
Microarrays
A microarray is a device in which beads or wells composed of thousands of unique DNA oligonucleotide probes are arrayed.
The Arrayed Primer Extension microarray (APEX) is oriented toward diagnosis and involves hybridization of a PCR-amplified mutant target DNA to an immobilized primer derived from a region adjacent to the loci of presumptive variants. After exten ding a single base labeled with either of four terminating dideoxynucleotide triphosphates (ddNTPs), the identities of newly incorporated nucleotides are determined. 17, 18) Commercially available RP diagnosis kits using APEX technology have been introduced. [19] [20] [21] There are two representative microarray platforms for genomewide association study (GWAS). The Affymetrix single-nucleotide polymorphism (SNP) array uses approximately 25 base-long oligonucleotides harboring all possible alleles at the polymorphic site. If there is a DNA matched with the probes, all SNPs can be identified. In contrast, the Illumina SNP array determines the polymorphism by a single base extension to the locus-specific primer. 22, 23) Both SNP arrays are currently used in RP mutation screening, [24] [25] [26] and
Illumina SNP genotyping arrays have been utilized for homozygosity screening of patients with RP. 27, 28) We previously screened a 336 RP cohort using microarrays. 24) We used the Illumina SNP array platform (GoldenGate Genotyping Assay) that included about 95 known mutations from 28 genes.
Ten RP-related mutations in five RP genes were identified in 26 of 336 patients (7.7%). Microarray offers a rapid screening, however the main shortcoming, as was the case for this study, is that it only detects known mutations. Therefore, customizable SNP array platforms were developed, and a novel mutation was identified using customized microarray-based resequencing. 26) In addition the detection rate was relatively low, less that 15%, for practical genetic counseling. 24, 26, 29) 
High resolution melting (HRM) analysis
HRM analysis determines the melting pattern of double-stranded DNA. HRM starts with PCR amplification of the target region using an intercalating fluorescent dye. As the temperature of the reaction mixture increases, the two strands of the amplicon DNA are separated (melted) and the fluorescent dye is released. The melting curve is obtained by measuring the fluorescence of the dye and the temperature. All genetic variants, including substitutions, inversions, and deletions, even at the level of a single nucleotide, are detected by comparing the melting curves between the test sample and a wild-type reference. In addition to its sensitivity, HRM is relatively inexpensive, because reaction and analysis are performed in the same device using a simple process. 30, 31) However, deletions of multiple exons may not be detected because PCR is required. 32) Typical amplicon lengths ranging between 100-300 bp are recommended. RP mutations were screened using HRM analysis. 33, 34) Aguirre-Lamban et al.
showed that HRM is more accurate than denaturing high-performance liquid chromatography (dHPLC) using it in ABCA4 gene screening of RP.
33)

Multiplex Ligation-dependent Probe Amplification (MLPA)
MLPA utilizes multiplex PCR for screening and the two halves of probes targeting the specific sequence. A universal primer flanks each end of the probe and a fluorescent tag is added at one end. After hybridization to the target sequence, the probes are ligated to reconstitute the full-length probe and PCR-amplified. The probes differ in length and are separated and identified using capillary electrophoresis. The amounts of ligated probe will be proportional to the target copy number. By analyzing the peak of fluorescence emission, either a duplication or deletion of the target region can be identified. 35) In particular, MLPA can detect large genomic deletions and insertion unlike microarray, dHPLC and HRM. The use of MLPA has contributed to identifying mutations in patients with RP.
36, 37)
Sequencing methods
Dideoxy DNA sequencing (Sanger sequencing)
This enzymatic sequencing method was invented by Frederick Sanger and is simply called "Sanger sequencing." It uses chainterminating ddNTPs that are similar to their dNTP counterparts abruptly terminating DNA synthesis. Current automated sequencing platforms utilize capillary electrophoresis to make reading the sequence a highly efficient process. Dideoxy termination sequencing is the most accurate method; however, it is ineffective for determining genome-scale sequences. We performed direct Sanger sequencing of RHO in 302 RP patients using a capillary DNA analyzer. One novel mutation and four known mutations in 6 probands were identified. RHO mutations are present in about 2% of Korean RP patients. This study illustrates the continued high value of Sanger sequencing for analyzing specific target regions.
Next-generation sequencing (NGS)
NGS utilizes fundamentally different sequencing technologies that were developed after the mid-2000s. A distinct feature is that NGS does not require polyacrylamide gel electrophoresis. NGS comprises 3 steps as follows: template preparation, sequencing, and combined imaging and data analysis. Each step can be performed using different several methods, and established commercial platforms use them in various combinations. A representative workflow is described here.
1) Template preparation
Generating a nonbiased source of nucleic acids is an important starting point. Randomly fragmented small genomic DNAs are called fragment templates or mate-pair templates depending on how they are created. These templates are immobilized to a support, which provides a platform for massively parallel sequencing.
In solid-phase amplification, forward or reverse primers are compactly attached to a glass slide. The templates are hybridized to the immobilized primers and form clusters for sequencing. Template DNA is clonally expanded using distinct "bridge PCR amplification."
2) Sequencing Cyclic reversible termination is a method that involves repetitive incorporation of a nucleotide modified with a terminating group and fluorescent dye, acquiring a fluorescent image, and cleaving the dye and the terminating group. After washing the unincorporated nucleotide, the next cycle is started. 38) Single nucleotide addition (Pyrosequencing) measures the proportional release of inorganic pyrophosphate using a chemilumine scent reaction and a DNA polymerase modified to add a sing le nucleotide at a time instead of a terminating nucleotide described above. [39] [40] [41] Real-time sequencing identifies newly incorporated nucleotide without halting DNA synthesis. 42) 3) Genome alignment and assembly In completing the short NGS reads, fragmented base sequences can be aligned to the known reference sequence or can be assembled de novo. [43] [44] [45] The alignment approach is less expensive and faster, however it is problematic when the reads are in repetitive regions or may not exist in the reference genome.
46)
The most widely used platform employs solid phase amplification and cyclic reversible termination. The concordance and false-positive rates are 99.5% and 2.5%, respectively, for detecting single nucleotide variants. 47) Although NGS is constantly improving in accuracy, it has never surpassed Sanger sequencing. Therefore, Sanger sequencing is still considered the gold standard.
Targeted resequencing
Despite the advent of massively parallel sequencing techniques that enable individual laboratories to sequence a whole human genome, whole genome sequencing is still expensive. Recent studies have introduced new methods to target larger regions of the human genome, which are suited to available massively parallel sequencing techniques and are described as genome capture or genome enrichment.
Targeted resequencing has been used to identify mutations in known and novel genes that cause hereditary disorders, such as familial exudative vitreoretinopathy and recessive non syndromic hearing loss discovered.
48, 49)
Unbiased sequencing approaches-Exome sequencing
Conventional genetic research tools, such as linkage mapping or candidate gene resequencing, have identified one-third to one-half of the loci underlying Mendelian inherited disorders. 50) However, there are several limitations to conventional gene discovery strategies. These include the scarcity of available large families, patients, locus heterogeneity, and reduced penetrance.
Conventional gene discovery depends on the biased sequencing of only a part of an entire genome. NGS has enabled sequencing at very low cost compared to conventional methods and unbiased sequencing such as whole exome sequencing or whole genome sequencing. Whole exome sequencing depends on targeted capture and massively parallel sequencing. Although the exome represents approximately 1% of a whole exome, sequencing can be a successful strategy for discovering a rare allele underlying a Mendelian-inherited disease. First, positional cloning focusing on protein coding region has been effective in studying monogenic disorders, 50) and most of the known causal alleles of such diseases are caused by mutations in protein coding regions. 51) Second, most protein-altering variants, such as missense, nonsense, or indel mutations are predicted to be significant. 52) Therefore, the exome represents a concentrated core that can be exploited for identifying causal variants of genetic disorders.
The most important aspect of exome sequencing is to confirm the causal variants among numerous mutations. The section that follows explains how causal mutations can be identified.
Discrete filtering
Discrete filtering depends on the assumption that variants found in a normal population cannot be a causal allele underlying a rare hereditary disease. This method depends on publicly accessible databases of known genetic variants. There are also several limitations to discrete filtering. For example, the database may contain erro neous pathologic variants. And a rarely occurring variant in normal population can be a real pathologic allele, this situation may occur for recessive traits because of the carrier state of heterozygous recessive genotypes. 53) 
Stratifying candidates after discrete filtering
Candidate alleles can be stratified according to their predicted severity. For example, frameshift or stop codons can be given greater weight than missense variants. Further, candidate alleles can be stratified according to functional properties of the encoded protein. Alternatively, highly conserved sequences can provide insights. Because mutations of conserved sequence are likely to be deleterious, they can contribute to making selections.
Filtering using tests of association
Two-sample tests, which compare unrelated individuals with the same phenotype to controls, can mitigate the problems of discrete filtering or suggest an adequate sample size for overcoming complicating factors. As the documentation of the exome dataset increases in quality, the ability to detect causal alleles will improve.
Pedigree information
Pedigree information is valuable for reducing the number of candidate alleles of a Mendelian disorder. In the absence of mapping data, sequencing the most genetically unrelated individuals is helpful. If mapping data is available, the sequences of two individuals whose haplotypes overlap the least are determined. In a de novo case, sequencing the DNA of parents and their offspring is an effective approach.
Defining the exome in its entirety faces some significant obstacles. First, the available exome database is not perfect. Moreover, sequencing regions other than the exome will provide useful information, such as the identity of microRNAs or promoter regions. Second, technical failure can occur due to inadequate coverage or incorrect variant calling. Either poor capturing ability or poor sequencing efficiency can cause inadequate coverage. Analy tical failure is yet another problem and can originate from the limitations of discrete filtering. If an etiological allele exists in a control dataset because of reduced penetrance, false-negative calls can be made. A false-positive call that identifies a nondisease-causing allele can pass filtering in cases of segmental duplication such as a processed pseudogene.
Whole exome sequencing can be applied to the diagnosis of inherited diseases characterized by atypical manifestations or for which only incomplete laboratory criteria are available as well as to the discovery of novel mutations. For example, several studies using exome sequencing have revealed novel mutations in patients with RP. [54] [55] [56] Bowne et al. revealed novel RPE65 mutation using combination of candidate gene screening and whole-exome sequencing. 54) This was the first report of AD pattern in RPE65 mutation. Zuchner et al. identified novel causal DHDDS gene in a single, one-generation family and demonstrated the usefulness of combining whole-exome sequencing with rapid in vivo studies. Further, exome sequencing can be used to screen for carriers of rare recessive diseases.
57)
Closing remarks
Whole exome or genome sequencing will be feasible in the near future because of lowering costs. One may guess that capturing the target will still be required. Despite gradual progress in sequencing technology, we should always consider limited resources and cost-effectiveness. Capture experiments allow sequencing more samples but with limited capacity. Therefore, it seems reasonable to conclude that targeted sequencing will be used along with whole-genome or whole-exome sequencing. For example, unbiased sequencing can be used for discovering the unrevealed one-half of causal genes of RP, and targeted sequencing can be adopted for practical molecular diagnosis.
